Information Provided By:
Fly News Breaks for February 14, 2020
DXCM
Feb 14, 2020 | 08:06 EDT
Oppenheimer analyst Steven Lichtman raised his price target for DexCom to $285 from $250 following the company's Q4 results, with sales ahead of January's pre-announcement and operating margin well ahead of estimates. While competitive dynamics continue to bear watching, Lichtman says near-term tailwinds remain including overall strong CGM market growth, pharmacy channel expansion, recent G6 Medicare launch and solid international expansion.
News For DXCM From the Last 2 Days
There are no results for your query DXCM
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.